{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:34:22Z","timestamp":1787160862793,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A disintegrin and metalloproteinase 8 (ADAM8) has been implicated in eosinophilic inflammation; however, its role in chronic rhinosinusitis with nasal polyps (CRSwNP) remains to be elucidated. This study aimed to investigate the predictive significance of ADAM8 levels in nasal secretions for the endotypes and disease control status of CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort comprising 120 CRSwNP patients and 45 healthy controls (HCs) was assembled, delineating 53 non-eosinophilic CRSwNP (neCRSwNP) and 67 eosinophilic CRSwNP (eCRSwNP) patients. Immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were utilized to measure ADAM8 levels in nasal mucosal tissues and secretions from all participants. The receiver operating characteristic (ROC) curves and Pearson correlation analysis were employed to assess the predictive capability of ADAM8 levels in predictiving CRSwNP endotypes and disease control status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ADAM8 levels in nasal secretions were elevated in CRSwNP patients compared to HCs, with a more pronounced increase observed in eCRSwNP patients. Elevated ADAM8 concentrations in nasal secretions were positively correlated with peripheral blood eosinophil counts and percentages, tissue eosinophil counts, serum total IgE, Lund\u2013Mackay scores, and Lund-Kennedy scores. Ultimately, 103 CRSwNP patients completed the follow-up protocol, with 72 classified as the controlled group and 31 as the uncontrolled group. Uncontrolled CRSwNP patients exhibited significantly higher ADAM8 levels in nasal secretions compared to the controlled group. The ROC curves indicated that ADAM8 in nasal secretions exhibits robust discriminatory capacity for eCRSwNP and postoperative disease control status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ADAM8 in nasal secretions emerges as a potential novel biomarker for the prognostication of CRSwNP endotypes and the postoperative disease control status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2024.1488441","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T01:11:13Z","timestamp":1731287473000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing the predictive potential of ADAM8 for disease control in chronic rhinosinusitis with nasal polyps"],"prefix":"10.3389","volume":"5","author":[{"given":"Peiqiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaci.2022.04.013","article-title":"Current insight into treatment of chronic rhinosinusitis: phenotypes, endotypes, and implications for targeted therapeutics","volume":"150","author":"Chapurin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaci.2024.04.019","article-title":"ALOX15+ M2 macrophages contribute to epithelial remodeling in eosinophilic chronic rhinosinusitis with nasal polyps","volume":"154","author":"Liu","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaci.2009.05.017","article-title":"Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese","volume":"124","author":"Cao","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jaci.2024.05.030","article-title":"Nasal brushing molecular endotyping distinguishes patients with chronic rhinosinusitis with nasal polyps with better response to dupilumab","volume":"154","author":"Gayvert","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/alr.23319","article-title":"Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps","volume":"14","author":"De Corso","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ACI.0000000000000588","article-title":"Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis","volume":"20","author":"Ryu","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2174\/138161209788682361","article-title":"ADAM8\/MS2\/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies","volume":"15","author":"Koller","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/187152808785107598","article-title":"ADAM8 in allergy","volume":"7","author":"Matsuno","year":"2008","journal-title":"Inflamm Allergy Drug Targets"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1111\/febs.17034","article-title":"A jack of all trades - ADAM8 as a signaling hub in inflammation and cancer","volume":"291","author":"Cook","year":"2024","journal-title":"FEBS J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaci.2006.12.665","article-title":"Increased expression of ADAM33 and ADAM8 with disease progression in asthma","volume":"119","author":"Foley","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1164\/rccm.201707-1331OC","article-title":"A disintegrin and metalloproteinase domain-8: a novel protective proteinase in chronic obstructive pulmonary disease","volume":"198","author":"Polverino","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00428-009-0748-4","article-title":"Expression of ADAMs (\u201ca disintegrin and metalloprotease\u201d) in the human lung","volume":"454","author":"Dijkstra","year":"2009","journal-title":"Virchows Arch"},{"key":"B13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2119\/2006-00028.Paulissen","article-title":"Expression of ADAMs and their inhibitors in sputum from patients with asthma","volume":"12","author":"Paulissen","year":"2006","journal-title":"Mol Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/cea.12223","article-title":"Sputum ADAM8 expression is increased in severe asthma and COPD","volume":"44","author":"Oreo","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000097359","article-title":"Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia","volume":"142","author":"Matsuno","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.rmed.2009.06.018","article-title":"Increased serum ADAM8 concentration in patients with drug-induced eosinophilic pneumonia-ADAM8 expression depends on a the allergen route of entry","volume":"104","author":"Matsuno","year":"2010","journal-title":"Respir Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/coa.13949","article-title":"A novel risk score for disease control prediction of chronic rhinosinusitis","volume":"47","author":"Jiang","year":"2022","journal-title":"Clin Otolaryngol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1007\/s00405-024-08695-w","article-title":"Association of mucus eosinophil-derived neurotoxin levels with disease control status in patients with chronic rhinosinusitis","volume":"281","author":"Huang","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.4168\/aair.2019.11.4.482","article-title":"Comparison of corticosteroids by 3 approaches to the treatment of chronic rhinosinusitis with nasal polyps","volume":"11","author":"Zhang","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2500\/aap.2021.42.210004","article-title":"Evaluation of nasal symptoms to distinguish eosinophilic from noneosinophilic nasal polyps based on peripheral blood","volume":"42","author":"Pan","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/19458924221111830","article-title":"Utilization of nasal mucus to investigate the pathophysiology of chronic rhinosinusitis","volume":"36","author":"Parra-Ferro","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/all.13489","article-title":"Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps","volume":"74","author":"Zhang","year":"2019","journal-title":"Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1165\/rcmb.2004-0026OC","article-title":"Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma","volume":"31","author":"King","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000516847","article-title":"Eosinophils correlate with epithelial-mesenchymal transition in chronic rhinosinusitis with nasal polyps","volume":"84","author":"Wang","year":"2022","journal-title":"ORL"},{"key":"B27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4193\/Rhin22.200","article-title":"Evaluating treatment response to mepolizumab in patients with severe CRSwNP","volume":"61","author":"Hopkins","year":"2023","journal-title":"Rhinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1488441\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T01:11:15Z","timestamp":1731287475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2024.1488441\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":30,"alternative-id":["10.3389\/falgy.2024.1488441"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2024.1488441","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"article-number":"1488441"}}